

SECURITIES AND EXCHANGE COMMISSION

FORM 1-U

Filing Date: **2023-03-24** | Period of Report: **2023-03-17**
SEC Accession No. [0001213900-23-022816](#)

([HTML Version](#) on [secdatabase.com](#))

FILER

Emerald Health Pharmaceuticals Inc.

CIK: **1700800** | IRS No.: **820669961** | State of Incorpor.: **DE** | Fiscal Year End: **1231**
Type: **1-U** | Act: **33** | File No.: **24R-00152** | Film No.: **23760163**
SIC: **2834** Pharmaceutical preparations

Mailing Address

5910 PACIFIC CENTER BLVD
SUITE 320,
SAN DIEGO CA 92121

Business Address

5910 PACIFIC CENTER BLVD
SUITE 320,
SAN DIEGO CA 92121
(858) 352-0622

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 1-U

CURRENT REPORT PURSUANT TO REGULATION A

Date of Report (Date of earliest event reported): **March 17, 2023**

Emerald Health Pharmaceuticals Inc.
(Exact name of issuer as specified in its charter)

Delaware
State or other jurisdiction of incorporation or organization

82-0669961
(I.R.S. Employer Identification No.)

5910 Pacific Center Blvd., Suite 320, San Diego, CA 92121
(Full mailing address of principal executive offices)

(858) 352 - 0622
(Issuer's telephone number, including area code)

Common stock, par value \$0.0001
(Title of each class of securities issued pursuant to Regulation A)

Item 9. Other Events

On March 17, 2023, Emerald Health Therapeutics, Inc. (the "Company") filed a certificate of dissolution with the Delaware secretary of state and officially dissolved. The Company is in the process of winding down and liquidating pursuant to the Plan of Liquidation and Dissolution approved by the Company's Board of Directors and the Company's stockholders.

As of the date of this report, the Company's liabilities greatly exceed its cash balance and thus the Company does not anticipate there to be any assets immediately available for distribution to its stockholders.

SIGNATURES

Pursuant to the requirements of Regulation A, the issuer has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**EMERALD HEALTH PHARMACEUTICALS
INC.,**
a Delaware corporation

By: /s/ Joe Lugo
Joe Lugo
Interim CEO

Date: March 24, 2023